镓-68-PSMA-11 PET/CT与氟-18-氟化钠PET/CT在放射性核素治疗前转移性前列腺癌患者骨转移评估中的比较
该研究回顾性分析16例已知骨转移、拟行放射性核素治疗的转移性前列腺癌患者,比较镓-68-PSMA-11 PET/CT与氟-18-氟化钠PET/CT对骨转移的诊断效能。氟-18-氟化钠PET检出468个阳性病灶,镓-68-PSMA-11 PET仅351个病灶阳性(75.0%)。作者认为在拟行放射性核素治疗的晚期前列腺癌患者中,氟-18-氟化钠PET/CT检测到的病理性骨病灶数量更多,并建议在骨转移患者治疗前再分期时联合使用两种显像。
要点
- 氟-18-氟化钠PET检出468个疑似骨转移病灶,镓-68-PSMA-11 PET仅351个病灶阳性(75.0%)。
- 氟-18-氟化钠PET病灶中位SUVmax为27.0,高于镓-68-PSMA-11 PET的6.0(p < 0.001)。
- 氟-18-氟化钠PET肿瘤/本底比值中位9.8,高于镓-68-PSMA-11 PET的5.9(p = 0.042)。
核心结论
- 与镓-68-PSMA-11 PET/CT相比,氟-18-氟化钠PET/CT在拟行放射性核素治疗的晚期前列腺癌患者中检测到更多病理性骨病灶。
- 作者认为,对于有骨转移的前列腺癌患者,在开始或修改治疗前再分期时,镓-68-PSMA-11 PET应与氟-18-氟化钠PET联合使用。
研究设计与样本
- 回顾性分析16例已知骨转移、拟行放射性核素治疗前评估转移负荷的转移性前列腺癌患者,均接受镓-68-PSMA-11 PET/CT和氟-18-氟化钠PET/CT。
- 诊断效能基于病灶水平比较,骨转移由CT或随访PET扫描确认。
主要发现
- 氟-18-氟化钠PET检出468个疑似骨转移阳性病灶,其中351个在镓-68-PSMA-11 PET上也判为阳性(75.0%)。
- 病理性骨病灶的示踪剂摄取强度氟-18-氟化钠PET中位SUVmax为27.0,高于镓-68-PSMA-11 PET的6.0(p < 0.001)。
- 正常骨本底活性镓-68-PSMA-11 PET中位SUVmax为1.0,低于氟-18-氟化钠PET的2.7,但肿瘤/本底比值氟-18-氟化钠PET中位9.8,高于镓-68-PSMA-11 PET的5.9(p = 0.042)。
- 基于CT形态学特征,氟-18-氟化钠PET在成骨性病灶中位SUVmax为23.6、溶骨性病灶为35.0、CT不可见病灶为19.0,镓-68-PSMA-11 PET相应为5.0、29.5和7.5。
- 氟-18-氟化钠PET与镓-68-PSMA-11 PET的示踪剂摄取强度在成骨性病灶(p < 0.001)和CT不可见病灶(p = 0.012)中差异有统计学意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The purpose of this study was to investigate the diagnostic performance of 68Ga-PSMA-11 PET/CT in the evaluation of bone metastases in metastatic prostate cancer (PC) patients scheduled for radionuclide therapy in comparison to [18F]sodium fluoride (18F-NaF) PET/CT. METHODS: Sixteen metastatic PC patients with known skeletal metastases, who underwent both 68Ga-PSMA-11 PET/CT and 18F-NaF PET/CT for assessment of metastatic burden prior to radionuclide therapy, were analysed retrospectively. The performance of both tracers was calculated on a lesion-based comparison. Intensity of tracer accumulation of pathologic bone lesions on 18F-NaF PET and 68Ga-PSMA-11 PET was measured with maximum standardized uptake values (SUVmax) and compared to background activity of normal bone. In addition, SUVmax values of PET-positive bone lesions were analysed with respect to morphologic characteristics on CT. Bone metastases were either confirmed by CT or follow-up PET scan. RESULTS: In contrast to 468 PET-positive lesions suggestive of bone metastases on 18F-NaF PET, only 351 of the lesions were also judged positive on 68Ga-PSMA-11 PET (75.0%). Intensity of tracer accumulation of pathologic skeletal lesions was significantly higher on 18F-NaF PET compared to 68Ga-PSMA-11 PET, showing a median SUVmax of 27.0 and 6.0, respectively (p < 0.001). Background activity of normal bone was lower on 68Ga-PSMA-11 PET, with a median SUVmax of 1.0 in comparison to 2.7 on 18F-NaF PET; however, tumour to background ratio was significantly higher on 18F-NaF PET (9.8 versus 5.9 on 68Ga-PSMA-11 PET; p = 0.042). Based on morphologic lesion characterisation on CT, 18F-NaF PET revealed median SUVmax values of 23.6 for osteosclerotic, 35.0 for osteolytic, and 19.0 for lesions not visible on CT, whereas on 68Ga-PSMA-11 PET median SUVmax values of 5.0 in osteosclerotic, 29.5 in osteolytic, and 7.5 in lesions not seen on CT were measured. Intensity of tracer accumulation between18F-NaF PET and 68Ga-PSMA-11 PET was significantly higher in osteosclerotic (p < 0.001) and lesions not visible on CT (p = 0.012). CONCLUSION: In comparison to 68Ga-PSMA-11 PET/CT, 18F-NaF PET/CT detects a higher number of pathologic bone lesions in advanced stage PC patients scheduled for radionuclide therapy. Our data suggest that 68Ga-PSMA-11 PET should be combined with 18F-NaF PET in PC patients with skeletal metastases for restaging prior to initiation or modification of therapy.
引用
- Uprimny C, Svirydenka A, Fritz J, et al. Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. Eur J Nucl Med Mol Imaging. 2018. PMID: 29766246. doi:10.1007/s00259-018-4048-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。